INFER-MED Kft

Futó vizsgálatok

• Még nem toboroz

  A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD

  2026-525216-34-00· 2. fázis· Forrás

• Toboroz

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· 2. fázis· Forrás

• Toboroz

  eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  NCT07177339· 3. fázis· Forrás

• Toboroz

  A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease

  2025-520473-40-00· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

  NCT06981078· 2. fázis· Forrás

• Toboroz

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· 3. fázis· Forrás

• Toboroz

  Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

  NCT06932263· 2. fázis· Forrás

• Fut, nem toboroz

  Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

  NCT06676319· 2. fázis· Forrás

• Meghívásos bevonás

  Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

  NCT06609239· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

  NCT06052267· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Krónikus obstruktív tüdőbetegség (COPD)5 toboroz
• Asztma1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

  NCT06264674· 3. fázis· Forrás

• Lezárult

  Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy

  2022-502208-64-00· 2. fázis· Forrás

• Lezárult

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· 2. fázis· Forrás